On July 8, 2026, the ELEVATE registration study of Betta Pharmaceuticals' ensartinib — a next-generation ALK tyrosine kinase inhibitor discovered and developed in Hangzhou — was published in full in The New England Journal of Medicine. In 274 Chinese patients with resected ALK-positive non-small cell lung cancer, two years of adjuvant ensartinib reduced the risk of disease recurrence or death by 80% compared with placebo (hazard ratio 0.20, 95% CI 0.10–0.37). The marketing application for the adjuvant indication has already been accepted in China. For international patients with resected ALK-positive NSCLC, the data positions China at the leading edge of adjuvant targeted therapy for lung cancer.
Lung cancer is the deadliest malignancy in China and the world. The National Cancer Center reported an estimated 1.06 million new cases and 733,300 deaths in China in 2022. Non-small cell lung cancer (NSCLC) makes up roughly 85% of those cases, and within NSCLC, about 5–7% of patients carry an ALK gene rearrangement. ALK-positive patients tend to be younger, light or never-smokers, and frequently diagnosed at an earlier stage when surgery is still possible.
That earlier stage is also where the problem sits. Even after what looks like a curative resection, ALK-positive NSCLC patients face a high risk of recurrence. Traditional adjuvant chemotherapy adds only modest benefit. The ELEVATE study asked a clean question: if you take the same targeted therapy that works against ALK in the metastatic setting and use it right after surgery, can you keep the disease from coming back?
To answer it, Betta and 56 Chinese medical centers enrolled 274 patients with stage IB to IIIB (T3N2M0) ALK-positive NSCLC whose tumors had been fully resected and who had completed any planned adjuvant chemotherapy. Patients were randomized 1:1 to oral ensartinib or placebo. ELEVATE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind registration study — the standard of evidence the NMPA and FDA expect to support a marketing indication.
| Outcome | Ensartinib | Placebo | Effect |
|---|---|---|---|
| 2-year disease-free survival (Stage II–IIIB) | 86.4% | 53.5% | HR 0.20 (95% CI 0.11–0.38) |
| 2-year disease-free survival (Stage IB–IIIB) | — | — | HR 0.20 (95% CI 0.10–0.37) |
| Recurrence or death risk reduction | ~80% | ||
A hazard ratio of 0.20 means the recurrence or death event rate in the ensartinib group was one-fifth the rate in the placebo group over the same period. In the Stage IB–IIIB population the effect was the same: an 80% reduction in risk.
Ensartinib is a next-generation ALK inhibitor designed in China. Betta Pharmaceuticals, headquartered in Hangzhou, developed it together with its U.S. subsidiary Xcovery. It is not a re-packaging of an older drug; it is a separate molecular entity with its own selectivity profile, CNS penetration, and resistance coverage.
Three things make ensartinib relevant to this specific clinical moment:
“The publication of the ELEVATE study in NEJM represents high recognition from the international medical community of the scientific value and clinical significance of this research. It is not only an important milestone for Betta but also a landmark achievement showcasing Chinese clinical oncology research on the global academic stage.”
— Dr. Ding Lieming, Chairman and CEO of Betta Pharmaceuticals
If you are reading this as a patient or family member, the practical question is: what does an adjuvant indication mean in plain terms?
In metastatic ALK-positive NSCLC, ensartinib (and the related ALK inhibitors alectinib, brigatinib, lorlatinib) are already standard. Those drugs work, and work well, but only after the cancer has already spread. Adjuvant therapy is the same drug, given earlier — right after surgery, before any visible recurrence. The point is to mop up microscopic disease that imaging cannot yet see. With ELEVATE's hazard ratio of 0.20, that mopping-up looks effective.
For an international patient weighing where to be treated, the change is concrete: a Chinese tertiary cancer center can now discuss ensartinib as an adjuvant option, with the supporting evidence published in the world's most-cited general medical journal. That conversation is available in a way it was not before last week.
ELEVATE is not the only recent Chinese-led lung cancer story in a top-tier journal. Adjuvant EGFR-targeted therapy in EGFR-mutant NSCLC (the ADAURA trial with osimertinib) has been the dominant paradigm since 2020. ALK-positive disease has been waiting for its equivalent. ELEVATE is, in effect, the ADAURA for ALK.
Three wider points are worth keeping in mind:
For an international patient who has had surgery for ALK-positive NSCLC and is weighing adjuvant therapy, the relevant questions are now:
For patients from Southeast Asia, Russia and Central Asia, the Middle East, and Africa — the patient population that the [cancer-treatment-china-2026 guide](/blog/cancer-treatment-china-2026.html) describes in detail — the practical implication is that Chinese tertiary cancer centers can now offer adjuvant ensartinib through clinical access pathways once the NMPA approval lands. Cost is a separate question (see below).
Ensartinib's Chinese retail price sits in the mid-range of next-generation ALK inhibitors. After China’s 2021 National Reimbursement Drug List (NRDL) negotiations and subsequent price cuts, ensartinib became reimbursable for its approved indications — typically with 70–80% reimbursement for insured Chinese patients, leaving out-of-pocket costs in the range of several thousand yuan per month. The drug has also been added to several city-level supplemental insurance schemes.
For international patients treated in China, the situation is different: international patients are generally not enrolled in the basic Chinese social insurance system, so they pay the hospital's international-department pricing. Quoted all-in costs for two years of adjuvant ensartinib treatment (drug + monitoring + outpatient visits) at major Chinese tertiary cancer centers typically fall between $25,000 and $50,000 — substantially below U.S. branded ALK inhibitor courses, which routinely run into six figures annually before insurance.
For a side-by-side comparison with other oncology and CAR-T costs in China, the [cancer-treatment-cost-china guide](/blog/cancer-treatment-cost-china.html) is the current reference. The [best-cancer-hospitals-china-2026 list](/blog/best-cancer-hospitals-china-2026.html) names the specific tertiary centers where this therapy would be administered.
Three concrete readouts will follow from this publication:
ELEVATE is the first Phase 3 study of an ALK inhibitor used adjuvantly in resected ALK-positive NSCLC to publish in NEJM with a hazard ratio this favorable. Ensartinib is a Chinese-discovered, Chinese-developed next-generation ALK inhibitor with already-approved first-line and second-line indications in China and in the United States. For international patients with resected ALK-positive lung cancer, the publication is a marker that Chinese tertiary cancer centers now have a complete evidence story for the disease — from surgery, to adjuvant targeted therapy, to advanced-stage treatment — and that story is now sitting in the world's most-cited medical journal.
Finding the right hospital in China can be overwhelming. Let us help — free, no commitment.
⏳ Most cases get a hospital match within 24 hours